Media headlines about Mylan (NASDAQ:MYL) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mylan earned a news impact score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.5024699700496 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Global Flu Vaccine Market 2018-Sanofi Pasteur, Mylan, Pfizer, Pfizer, Johnson & Johnson (journalhealthcare.com)
- How to Trade these Stock After an unavoidable Selloff – Mylan NV, NASDAQ: MYL), Amarin Corporation plc, (NASDAQ … (dailynysenews.com)
- [$$] Drugmakers take unorthodox route to boosting biosimilars (finance.yahoo.com)
- Global Hormone Replacement Therapy (HRT) Market Analysis 2018 Mylan Laboratories, Pfizer, Abbott Laboratories … (newspharmaceuticals.com)
- Global Xeloda Market Outlook 2018-2023 : Roche, Teva, Mylan, Hikma, Hengrui Medicine (journalhealthcare.com)
Several research analysts have recently weighed in on MYL shares. BidaskClub cut Mylan from a “strong-buy” rating to a “buy” rating in a report on Friday, January 26th. Susquehanna Bancshares restated a “positive” rating and set a $55.00 target price (up from $47.00) on shares of Mylan in a report on Thursday, January 25th. Zacks Investment Research upgraded Mylan from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Morgan Stanley upgraded Mylan from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $39.00 to $50.00 in a report on Tuesday, March 6th. Finally, Wells Fargo set a $43.00 target price on Mylan and gave the stock a “hold” rating in a report on Thursday, January 18th. Eight equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $47.02.
MYL traded down $0.24 during trading hours on Wednesday, reaching $40.74. The company’s stock had a trading volume of 2,460,988 shares, compared to its average volume of 5,117,541. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82. The stock has a market capitalization of $20,961.91, a PE ratio of 8.93, a P/E/G ratio of 1.30 and a beta of 1.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.13.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, February 28th. The company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The company had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the prior year, the firm earned $1.57 earnings per share. The firm’s revenue was down .9% compared to the same quarter last year. equities research analysts forecast that Mylan will post 5.36 earnings per share for the current fiscal year.
In other Mylan news, insider Paul Campbell sold 7,030 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total transaction of $309,390.30. Following the transaction, the insider now directly owns 17,054 shares in the company, valued at $750,546.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert J. Coury sold 50,000 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $43.41, for a total value of $2,170,500.00. The disclosure for this sale can be found here. Insiders have sold 269,287 shares of company stock worth $11,034,960 over the last 90 days. 0.69% of the stock is owned by insiders.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.